From the makers of 
Track & Manage All Of Your Investments
Try It Now!
| |||||||||
FierceBiotech
5 hrs ago
Comment
Metacrine raised $65 million to launch phase 1 clinical development of its FXR agonist program in NASH and gastrointestinal diseases, set to start later this month.
MedPage Today
Apr 15
Comment
(MedPage Today) -- Phase II trial interim analysis found dose-dependent response, good safety profile
GenEng News
Jul 12
Comment
The typical western diet, which is high in fat and sugar, has long been suspected to have a negative impact on human health. Now, a team of investigators at UC Davis has just released new findings showing that a Western diet fed to mice resulted...
Benzinga
Jul 6
Comment
Perhaps because it is not as glamorous as the technology or health care sector, the industrial sector does not often get the love it deserves. The same can be true of some of the exchange-traded funds dedicated to industrial stocks, but a sturdy...
GenEng News
Apr 18
Comment
Novartis and Allergan have agreed to carry out a Phase IIb study combining one of Novartis’ farnesoid X receptor (FXR) agonist candidates with Allergan’s late-stage C-C chemokine receptor types 2 and 5 ( CCR2/5) blocker cenicriviroc (CVC) for...
GenEng News
Jan 5
Comment
Germany’s Phenex Pharmaceuticals confirmed receipt of a $100M milestone payment from Gilead Sciences, relating to continued clinical development of the synthetic, nonsteroidal farnesoid X receptor (FXR) agonist GS-9674 for the treatment of...
Forbes
Nov 17
Comment
The First Trust Industrials/Producer Durables AlphaDEX Fund ETF (FXR) is seeing unusually high volume in afternoon trading Thursday, with over 639,000 shares traded versus three month average volume of about 152,000. Shares of FXR were up about...
FierceBiotech
Feb 17
Comment
Forbion Capital Partners has rounded up members of the team that led Dezima to a $1.5 billion (€1.3 billion) takeover to mount an attempt to chase down Intercept Pharmaceuticals. The project, which is getting underway with a $15 million round...
Benzinga
Nov 15
Comment
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced results from three studies in primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC), that will be presented at the American Academy for the Study of Liver...
GenEng News
Jan 6
Comment
Gilead Sciences will acquire Phenex Pharmaceuticals’ Farnesoid X Receptor (FXR) program, consisting of small molecule FXR agonists designed to treat liver diseases that include nonalcoholic steatohepatitis (NASH), the companies said today. The...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail |
This article describes an exchange traded fund that tracks an index, commodity, currency, or varied basket of securites. View articles referencing this fund. |
TOP CONTRIBUTORS
First Trust Industrials AlphaDEX Fund (FXR)
Overview
The First Trust Industrials/Producer Durables AlphaDEX® Fund is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield, before fees and expenses, of an equity index called the StrataQuant® Industrials Index. [1]
Fund Information
- Fund Manager - First Trust Portfolios L.P.
- Inception Date - 05/08/2007
- Exchange – NYSE Arca
- Index Ticker - FXR
- Intra-day NAV Ticker - FXRIV
- Expense Ratio - 0.70%
Top Holdings
| Holdings | Percent (%) |
| Joy Global Inc. | 2.09 |
| Thomas & Betts Corporation | 2.07 |
| Overseas Shipholding Group, Inc. | 1.98 |
| Norfolk Southern Corporation | 1.97 |
| Bucyrus International, Inc. | 1.96 |
| Hubbell Incorporated (Class B) | 1.96 |
| AGCO Corporation | 1.93 |
| Flowserve Corporation | 1.93 |
| GATX Corporation | 1.89 |
| Lexmark International, Inc. | 1.85 |
Holdings as of 23/10/2009
Other Industrial ETFs
References
